Literature DB >> 16557680

Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.

C Urban1, N Mariano, J J Rahal, E Tay, C Ponio, T Koprivnjak, J Weiss.   

Abstract

Entities:  

Year:  2001        PMID： 16557680      PMCID： PMC90414          DOI： 10.1128/AAC.45.3.994-995.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  15 in total

1.  Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.

Authors:  P Fernandez-Viladrich; X Corbella; L Corral; F Tubau; A Mateu
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

Review 2.  Peptide antibiotics.

Authors:  R E Hancock; D S Chapple
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 3.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

4.  Acinetobacter.

Authors:  J J Rahal; C Urban
Journal:  Semin Respir Crit Care Med       Date:  2000       Impact factor: 3.119

5.  Bactericidal/permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: results of a multicenter phase II clinical trial. rBPI21 Acute Hemorrhagic Trauma Study Group.

Authors:  D Demetriades; J S Smith; L E Jacobson; M Moncure; J Minei; B J Nelson; P J Scannon
Journal:  J Trauma       Date:  1999-04

6.  Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis.

Authors:  B P Giroir; P A Quint; P Barton; E A Kirsch; L Kitchen; B Goldstein; B J Nelson; N J Wedel; S F Carroll; P J Scannon
Journal:  Lancet       Date:  1997-11-15       Impact factor: 79.321

7.  Antiendotoxin activity of cationic peptide antimicrobial agents.

Authors:  M Gough; R E Hancock; N M Kelly
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

8.  Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam.

Authors:  E S Go; C Urban; J Burns; B Kreiswirth; W Eisner; N Mariano; K Mosinka-Snipas; J J Rahal
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

9.  Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of gram-negative sepsis: role of bactericidal properties.

Authors:  W S Ammons; F R Kohn; A H Kung
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

Review 10.  Prospects for use of recombinant BPI in the treatment of gram-negative bacterial infections.

Authors:  P Elsbach; J Weiss
Journal:  Infect Agents Dis       Date:  1995-06
View more
  15 in total

1.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii.

Authors:  L A Arroyo; A García-Curiel; M E Pachón-Ibañez; A C Llanos; M Ruiz; J Pachón; J Aznar
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

Review 3.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

4.  High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.

Authors:  Tiffany A Thomas; Emily C Broun; Kirsten M Abildskov; Christine J Kubin; Jennifer Horan; Michael T Yin; Serge Cremers
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

5.  The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A.

Authors:  Luis A Arroyo; Carmen M Herrera; Lucia Fernandez; Jessica V Hankins; M Stephen Trent; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

6.  Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action.

Authors:  José María Saugar; María Jesús Rodríguez-Hernández; Beatriz G de la Torre; María Eugenia Pachón-Ibañez; María Fernández-Reyes; David Andreu; Jerónimo Pachón; Luis Rivas
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia.

Authors:  C Pichardo; M E Pachón-Ibañez; F Docobo-Perez; R López-Rojas; M E Jiménez-Mejías; A Garcia-Curiel; J Pachon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-02-25       Impact factor: 3.267

Review 8.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

9.  Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California.

Authors:  Sonya C Valentine; Deisy Contreras; Stephanie Tan; Lilian J Real; Sheena Chu; H Howard Xu
Journal:  J Clin Microbiol       Date:  2008-06-04       Impact factor: 5.948

Review 10.  Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy.

Authors:  Bora Shin; Woojun Park
Journal:  J Microbiol       Date:  2017-10-27       Impact factor: 3.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.